Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.America Stem Cell has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health.
Subscribe to our email newsletter
The grant will be used by America Stem Cell and Wake Forest Institute of Regenerative Medicine (WFIRM) scientists to explore the combination of ASC-101 and amniotic fluid-derived stem cells technologies.
America Stem Cell will use the award to expand the potential for therapeutic application of ASC-101 with amniotic fluid-derived stem cells and develop ASC-101 to yet another cell type.
America Stem Cell will also examine the effect of ASC-101-treated amniotic fluid-derived stem cells in an experimental model of compartment syndrome.
Co-Principal Investigator on the grant Leonard Miller said, "The successful combination of ASC-101 with amniotic fluid-derived stem cells would be directly relevant to improving the treatment of muscle damage that occurs following compartment syndrome as well as multiple other types of injuries."
America Stem Cell CEO Lynnet Koh said the combination of ASC-101 with amniotic fluid-derived stem cells could enhance the therapeutic and regenerative capacity of the cells and provide an off-the-shelf.
”ASC-101 is a transformative technology with the potential to improve clinical outcomes for patients undergoing a wide variety of cell therapies for the treatment of diseases such as graft versus host disease, diabetic complications, and ischemic diseases such as myocardial infarctions, retinopathy and critical limb ischemia." Koh added.